# NCT07229417 (NCT07229417)

> A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07229417
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Metastatic Endocrine Refractory; Triple Negative Invasive Lobular Carcinoma
- Interventions: Ivonescimab
- Enrollment: 29
- Primary outcome: Safety and adverse events (AEs)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct07229417